ArticleMovement disorders clinical practice2026
Switching from Levodopa/Carbidopa Intestinal Gel to Continuous Subcutaneous Foslevodopa/Carbidopa Infusion in Advanced Parkinson's Disease: A Case Series.
Article in Movement disorders clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Real-world experience with foslevodopa/foscarbidopa in Germany: therapeutic insights and lessons learned.Neurological research and practice · 2026Review
- Review
- Real-world implementation of continuous subcutaneous foslevodopa/foscarbidopa in advanced Parkinson's disease: first clinical experience from the Middle East.Therapeutic advances in neurological disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundContinuous subcutaneous foslevodopa/foscarbidopa infusion (CSFLI) is a novel non-surgical alternative to levodopa/carbidopa intestinal gel (LCIG) for advanced Parkinson's disease (aPD), but real-world switch data remain limited.
objectivesTo describe the feasibility, safety, and clinical effects of switching from LCIG to CSFLI.
methodsWe retrospectively reviewed eight aPD patients switched from LCIG to CSFLI at a single center between November 2024 and May 2025. Motor and non-motor symptoms, quality of life, and levodopa equivalent daily doses were assessed at baseline (M0) and six months (M6).
resultsSmall but significant improvements occurred in UPDRS part I, III, and IV and PDQ-8 scores at M6. Total LEDD remained stable. CSFLI was well tolerated with mild local skin reactions.
conclusionSwitching from LCIG to CSFLI is feasible and safe, providing stable dopaminergic delivery with modest symptomatic benefits in selected aPD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.